IL-HYATT-HOTELS
To share progress made across World of Care, the company’s Environmental, Social and Governance (ESG) platform, Hyatt Hotels Corporation (NYSE: H) today published its 2021 World of Care Highlights and Diversity, Equity and Inclusion (DE&I) Report to demonstrate how Hyatt is advancing care for the planet, people and responsible business.
“Caring for people so they can be their best has been at the core of Hyatt’s story for 65 years. Through World of Care, we embrace our responsibility and opportunity to work together to shape a more sustainable world and future,” said Margaret Egan, executive vice president and general counsel, Hyatt. “By intently focusing on driving progress against key ESG commitments like our environmental framework and Change Starts Here goals, we are holding ourselves accountable for continued action and progress in order to create the needed changes for our industry, society and planet.”
Hyatt Advances Diverse Workforce Representation
Following last year’s inaugural DE&I report, Hyatt’s 2021 workforce diversity data shows increased levels of representation of people of color across its U.S. workforce, as well as growth across nearly all races and ethnicities among colleagues, managers and leaders. Hyatt’s commitment to share progress annually serves as a critical benchmark to measure the strides made toward a more diverse, equitable and inclusive environment for colleagues.
Hyatt continues to work toward its 2025 DE&I goals around who it employs, supports and works with, outlined as part of its Change Starts Here commitments. With a focus on improving diverse vendor representation across its supply chain, Hyatt welcomed 220 new Black suppliers in 2021, with a continued focus on advancing progress looking ahead. For example, Revival Baltimore, which is part of the JdV by Hyatt brand, worked with Black-owned Black Acres Roastery to supply coffee to all hotel guestrooms and the property’s onsite coffee shop, ‘Dashery, and Hyatt Centric The Pike Long Beach recently welcomed Black-owned brewery Crowns & Hops to its Watercraft Lounge.
“At Hyatt, we believe in the power of belonging – of making people feel at home no matter where they are in the world. We constantly strive to reflect the world we care for with teams that achieve and grow together,” said Malaika Myers, chief human resources officer, Hyatt. “To advance our vision of a world of understanding and care, we must continue to prioritize DE&I across every dimension of our business and take action to make meaningful progress against our goals.”
Hyatt Announces Donation to Launch Human Trafficking Survivor Fund
In an effort to expand the hotel industry’s ongoing work to support human trafficking prevention and survivors, the Hyatt Hotels Foundation has announced a $500,000 donation to launch the “No Room for Trafficking Survivors Fund” in collaboration with the American Hotel & Lodging Association (AHLA). With the donation, and further support from the industry, the Survivors Fund will equip community-based organizations with the resources they need to engage and support survivors – from direct financial support of their short-term, baseline needs to career-related support that can empower and equip them on their path forward.
Hyatt Works to Advance Climate Action
Hyatt further accelerates its efforts to engage in more sustainable business practices as part of its environmental framework – focused on areas of climate change and water conservation, waste and circularity, responsible sourcing and thriving destinations.
In 2021, Hyatt received approval from the Science Based Targets initiative (SBTi) on its 2030 science-based target to reduce greenhouse gas emissions. Hyatt’s targets include reducing absolute scope 1 and 2 emissions, engaging key suppliers to set science-based targets by 2025, and decreasing additional scope 3 emissions.
Hyatt remains diligent in promoting initiatives that support progress toward its science-based target, which focus on energy conservation, efficient technology, building automation systems, advancing sustainable design considerations and more. An important ongoing focus will be on increasing the number of hotels that have on-site solar panels or are using one-hundred percent renewable electricity such as Hyatt Regency Amsterdam and Hyatt Regency Phoenix. Ongoing property efforts are also critical in achieving these targets, such as the ones displayed at Alila Villas Uluwatu through its on-site sustainability lab .
To learn more about Hyatt’s ESG efforts and progress, visit Hyatt.com/WorldofCare or browse the 2021 World of Care Highlights , 2021 DE&I Report and 2021 GRI Index .
The term “Hyatt” is used in this release for convenience to refer to Hyatt Hotels Corporation and/or one or more of its affiliates.
About Hyatt Hotels Corporation
Hyatt Hotels Corporation, headquartered in Chicago, is a leading global hospitality company guided by its purpose – to care for people so they can be their best. As of March 31, 2022, the Company’s portfolio included more than 1,150 hotels and all-inclusive properties in 71 countries across six continents. The Company's offering includes the Park Hyatt®, Miraval®, Grand Hyatt®, Alila®, Andaz®, The Unbound Collection by Hyatt®, Destination by Hyatt™, Hyatt Regency®, Hyatt®, Hyatt Ziva™, Hyatt Zilara™, Thompson Hotels®, Hyatt Centric®, Caption by Hyatt, JdV by Hyatt™, Hyatt House®, Hyatt Place®, UrCove, and Hyatt Residence Club® brands, as well as resort and hotel brands under the AMR™ Collection, including Secrets® Resorts & Spas, Dreams® Resorts & Spas, Breathless Resorts & Spas®, Zoëtry® Wellness & Spa Resorts, Vivid Hotels & Resorts®, Alua Hotels & Resorts®, and Sunscape® Resorts & Spas. Subsidiaries of the Company operate the World of Hyatt® loyalty program, ALG Vacations®, Unlimited Vacation Club®, Amstar DMC destination management services, and Trisept Solutions® technology services. For more information, please visit www.hyatt.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005967/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom